Research Analysts Issue Forecasts for XENE FY2025 Earnings

Key Points

• Analysts at Bloom Burton project that Xenon Pharmaceuticals will report earnings of (4.20) per share for FY2025, compared to the current consensus estimate of (3.10) per share.
• The stock has received a variety of ratings from research firms, with one analyst giving a Strong Buy, eleven rating it as a Buy, and one providing a Sell rating, reflecting mixed investor sentiment.
• Recent activities include CEO Ian Mortimer selling 25,000 shares for a total of $1,004,000, reducing his ownership by 44.40%.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Analysts at Bloom Burton issued their FY2025 EPS estimates for shares of Xenon Pharmaceuticals in a research note issued to investors on Tuesday, October 7th. Bloom Burton analyst D. Martin anticipates that the biopharmaceutical company will earn ($4.20) per share for the year. Bloom Burton has a "Strong-Buy" rating on the stock. The consensus estimate for Xenon Pharmaceuticals' current full-year earnings is ($3.10) per share.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The biopharmaceutical company reported ($1.07) earnings per share for the quarter, missing analysts' consensus estimates of ($1.03) by ($0.04). During the same quarter in the prior year, the firm earned ($0.75) EPS.

A number of other research firms have also recently weighed in on XENE. William Blair reissued an "outperform" rating on shares of Xenon Pharmaceuticals in a research report on Tuesday. Chardan Capital restated a "buy" rating and issued a $55.00 target price on shares of Xenon Pharmaceuticals in a research note on Tuesday. Wells Fargo & Company initiated coverage on shares of Xenon Pharmaceuticals in a research note on Wednesday, September 3rd. They issued an "overweight" rating and a $48.00 target price on the stock. Wedbush upped their target price on shares of Xenon Pharmaceuticals from $42.00 to $43.00 and gave the company an "outperform" rating in a research note on Tuesday, August 12th. Finally, Royal Bank Of Canada restated an "outperform" rating and issued a $55.00 target price on shares of Xenon Pharmaceuticals in a research note on Tuesday, September 2nd. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $53.30.

Xenon Pharmaceuticals Price Performance

NASDAQ:XENE opened at $39.25 on Thursday. The firm has a 50-day moving average of $37.23 and a two-hundred day moving average of $34.15. The stock has a market cap of $3.03 billion, a P/E ratio of -11.06 and a beta of 1.14. Xenon Pharmaceuticals has a 1-year low of $26.74 and a 1-year high of $46.00.

Institutional Investors Weigh In On Xenon Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. GF Fund Management CO. LTD. raised its stake in Xenon Pharmaceuticals by 21.9% during the first quarter. GF Fund Management CO. LTD. now owns 1,952 shares of the biopharmaceutical company's stock worth $65,000 after acquiring an additional 351 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in Xenon Pharmaceuticals by 15.7% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,964 shares of the biopharmaceutical company's stock worth $93,000 after acquiring an additional 403 shares during the period. Natixis Advisors LLC raised its stake in Xenon Pharmaceuticals by 1.9% during the first quarter. Natixis Advisors LLC now owns 24,010 shares of the biopharmaceutical company's stock worth $806,000 after acquiring an additional 456 shares during the period. Farther Finance Advisors LLC acquired a new stake in Xenon Pharmaceuticals during the second quarter worth about $25,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Xenon Pharmaceuticals during the first quarter worth about $30,000. Institutional investors and hedge funds own 95.45% of the company's stock.

Insiders Place Their Bets

In related news, CEO Ian Mortimer sold 25,000 shares of the stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $40.16, for a total transaction of $1,004,000.00. Following the sale, the chief executive officer owned 31,302 shares in the company, valued at $1,257,088.32. This represents a 44.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.07% of the stock is currently owned by company insiders.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.